New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTLIFE, LIFE, LIFE, CYCC, CYCC, CYCC, BLUE, BLUE, BLUE, PJC, PJC, PJC, STEM, STEM, STEM, ATHX, ATHX, ATHX, NBS, NBS, NBS, ONVO, ONVO, ONVO, CYTX, CYTX, CYTX, ISCO, ISCO, ISCOEBD Group to hold a conference
Biotech Showcase 2014 is being held in San Francisco on January 13-15.
News For LIFE;CYTX;ONVO;NBS;ATHX;STEM;PJC;BLUE;CYCC;ISCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
08:14 EDTCYTXCytori Therapeutics says company-supported trial in Japan to begin enrollment
Subscribe for More Information
July 28, 2015
09:18 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTCYTXCytori licensee Kerastem receives conditional FDA approval for alopecia trial
Cytori Therapeutics announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. FDA conditional Investigational Device Exemption approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness.The phase II study, known as the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the FDA IDE submission. The data will be presented in September at the 2015 International Society of Hair Restoration Surgery meeting in Chicago. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centers within the United States. The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density. In 2013, Bimini, a private medical technology company, acquired global and exclusive rights to commercialize Cytori Celution Technology for alopecia and hair related indications. Under the commercial agreement, Bimini will be responsible for all key activities including clinical studies, regulatory approvals, and market development. Bimini will acquire Cytori products at agreed upon transfer pricing and pay Cytori a perpetual royalty on sales.
July 27, 2015
10:40 EDTBLUEIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 23, 2015
13:44 EDTSTEMStemCells says patent infringement case against Neuralstem dismissed by court
Subscribe for More Information
08:07 EDTPJCPiper Jaffray reports Q2 adjusted EPS $1.19, consensus 98c
Subscribe for More Information
07:49 EDTSTEMNeuralstem awarded favorable court ruling in StemCell patent litigation
Subscribe for More Information
July 20, 2015
09:06 EDTPJCPiper Jaffray to acquire BMO municipal bond sales unit
Subscribe for More Information
08:12 EDTSTEMStemCells transplants first patient in clinical trial for macular degeneration
StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration
07:33 EDTSTEMInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTLIFEaTyr Pharma announces transitions in clinical developments
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use